An open‐label, phase 1 study, a single oral dose study analyzing pharmacokinetics and safety of aprocitentan
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Aprocitentan (Primary)
- Indications Hypertension; Resistant hypertension
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 22 Apr 2022 New trial record
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics